The aberrant expression of MicroRNA-137 (miR-137) is correlated with different tumors closely,miR-137 promoter methylation considered as one of the most important mechanisms through which miR-137 expression can be regulated.The degree of promoter methylation of miR-137 was significantly increased in tumors,but the frequencies varied.In addition,it correlated with different clinical and pathological characteristics in tumors.Furthermore,miR-137 promoter methylation indicated poor prognosis.miR-137 promoter methylation promoted the initiation and progression of tumors,it was of potential to be a biomarker and reversed the methylation status of miR-137 represented a novel strategy of cancer treatment.

Objective To evaluate the expression of FUNDC1 and its clinical significance in non-small cell lung cancer. Methods We used TCGA database to analyze the difference of mitochondrial receptors (DRP1, BNIP3, FUNDC1, NIX, RHEB, LC3, OPA1 and MFN1) expression between normal and NSCLC tissues, as well as its effect on the prognosis of NSCLC patients. Immunohistochemistry was used to detect FUNDC1 expression. The correlations between FUNDC1 expression and clinicopathological characteristics, prognosis were evaluated by SPSS 22.0 statistical software. Results FUNDC1 expression was increased in NSCLC tissues, compared with normal tissues. FUNDC1 expression was related to the degree of differentiation and lymph node metastasis, but not to gender, age, pathological type, distant metastasis or TNM classification. The Cox regression analysis showed that FUNDC1 protein expression, lymph node metastasis, differentiation degree were independent prognostic factors of NSCLC. Increased FUNDC1 expression was related to decreased OS and PFS (P < 0.01). Conclusion The up-regulation of FUNDC1 expression can affect the prognosis of patients with NSCLC. It may be a new potential target for treating with NSCLC.